GlassScriptPhysician profile
Hina Dalal
NPI 1285138677
$1,051.58
in general payments reported to CMS, 2019-2025
11 companies · $35.00 in 2025
The $35.00 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $101 · 2023: $518 · 2024: $397 · 2025: $35.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.24 |
| Education | $240.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $250.58 | 2022-2023 | |
| Genzyme Corporation | $176.91 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $111.49 | 2023 | Libtayo |
| Tempus Ai, INC | $87.13 | 2024 | Xt Cdx |
| Pfizer INC. | $84.99 | 2024 | |
| Seagen INC. | $81.99 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.99 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $58.74 | 2024 | Imfinzi |
| Incyte Corporation | $58.25 | 2023-2024 | Jakafi |
| Beigene USA, INC. | $35.00 | 2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $32.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hina Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.